CN114573570A - 一类α-突触核蛋白靶向化合物及其制备方法和应用 - Google Patents
一类α-突触核蛋白靶向化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114573570A CN114573570A CN202210159074.4A CN202210159074A CN114573570A CN 114573570 A CN114573570 A CN 114573570A CN 202210159074 A CN202210159074 A CN 202210159074A CN 114573570 A CN114573570 A CN 114573570A
- Authority
- CN
- China
- Prior art keywords
- compound
- synuclein
- alpha
- 400mhz
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 159
- 102000003802 alpha-Synuclein Human genes 0.000 title claims abstract description 115
- 108090000185 alpha-Synuclein Proteins 0.000 title claims abstract description 115
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 230000008685 targeting Effects 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 37
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 7
- 229940125797 compound 12 Drugs 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 5
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 5
- 229940126208 compound 22 Drugs 0.000 claims description 5
- 229940125851 compound 27 Drugs 0.000 claims description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229940126543 compound 14 Drugs 0.000 claims description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims description 2
- 229940127007 Compound 39 Drugs 0.000 claims description 2
- 102100037114 Elongin-C Human genes 0.000 claims description 2
- 101001011859 Homo sapiens Elongin-A Proteins 0.000 claims description 2
- 101001011846 Homo sapiens Elongin-B Proteins 0.000 claims description 2
- 101000881731 Homo sapiens Elongin-C Proteins 0.000 claims description 2
- 101000836005 Homo sapiens S-phase kinase-associated protein 1 Proteins 0.000 claims description 2
- 229940125878 compound 36 Drugs 0.000 claims description 2
- 229940126540 compound 41 Drugs 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 22
- 238000006731 degradation reaction Methods 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 230000003834 intracellular effect Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 11
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 7
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 239000003446 ligand Substances 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 5
- 238000012986 modification Methods 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 230000034512 ubiquitination Effects 0.000 abstract description 4
- 238000010798 ubiquitination Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 116
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 33
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 229910001868 water Inorganic materials 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000007858 starting material Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 239000000376 reactant Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000007429 general method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229940126639 Compound 33 Drugs 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 4
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000004262 preparative liquid chromatography Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 2
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- UIADWSXPNFQQCZ-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-phenyl-1,3-oxazol-2-yl]butanoic acid Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(OC=1C1=CC=CC=C1)CCCC(=O)O UIADWSXPNFQQCZ-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 208000032859 Synucleinopathies Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125876 compound 15a Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 1
- BMHMKWXYXFBWMI-UHFFFAOYSA-N 3,4-Methylenedioxyacetophenone Chemical compound CC(=O)C1=CC=C2OCOC2=C1 BMHMKWXYXFBWMI-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- 102000015367 CRBN Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000000765 microspectrophotometry Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于生物医药技术领域,具体涉及一类α‑突触核蛋白靶向化合物及其制备方法和应用。该类化合物同时包含α‑突触核蛋白配体、连接子和E3连接酶配体结构片段,能够招募细胞内的E3连接酶对α‑突触核蛋白进行泛素化修饰,进而借助UPS实现α‑突触核蛋白的化学诱导降解;并且经试验证明,该类化合物通过靶向α‑突触核蛋白并诱导其泛素化,可以达到显著降低胞内α‑突触核蛋白聚集体水平、提高细胞活力的效果,在治疗α‑突触核蛋白相关疾病领域具有较好的应用前景。
Description
技术领域
本发明属于生物医药技术领域。更具体地,涉及一类α-突触核蛋白靶向化合物及其制备方法和应用。
背景技术
研究发现,α-突触核蛋白(α-Synuclein)在一系列神经退行性疾病的发生和发展中扮演着核心的作用,所涉及到的疾病包括但不限于帕金森病(Parkinson’s disease,PD)、路易体痴呆(dementia with Lewy bodies,DLB)和多系统萎缩(multiple systematrophy,MSA)等,这些疾病被统称为突触核蛋白病(synucleopathies)。这些疾病患者的胞内蛋白稳态失衡,α-突触核蛋白过度聚集,形成特征性的路易小体(Lewy bodies),进而引发多巴胺能神经元的死亡。因此,在这些疾病的治疗过程中,通过药物调节胞内α-突触核蛋白的水平将成为一种有效、新颖的策略。
如中国专利申请CN110891565A公开了一种α-突触核蛋白的调控剂,可以抑制α-突触核蛋白的生成,显著降低细胞内α-突触核蛋白水平;中国专利申请CN113365616A公开了一种α-突触核蛋白的聚集抑制剂,可以抑制α-突触核蛋白单体的聚集,减少细胞内α-突触核蛋白聚集体的含量,从而降低α-突触核蛋白的细胞毒性。可见,已公开的传统靶向α-突触核蛋白药物大部分都是抑制α-突触核蛋白的生成、聚集或扩散,而不能直接将其清除。因此,有必要提供一类直接清除α-突触核蛋白的靶向降解化合物。
发明内容
本发明要解决的技术问题是克服现有靶向α-突触核蛋白的药物无法直接降解α-突触核蛋白的缺陷和不足,提供一类直接清除α-突触核蛋白的α-突触核蛋白靶向化合物。
本发明的目的是提供所述α-突触核蛋白靶向化合物的制备方法。
本发明另一目的是提供所述α-突触核蛋白靶向化合物的应用。
本发明另一目的是提供一类治疗α-突触核蛋白相关疾病的药物。
本发明上述目的通过以下技术方案实现:
一类α-突触核蛋白靶向化合物,其特征在于,所述α-突触核蛋白靶向化合物具有式(I)、式(II)或式(III)所示结构:
n为2或3。
优选地,所述α-突触核蛋白靶向化合物具有式(II)结构。
优选地,式中所述n为2。
更优选地,所述α-突触核蛋白靶向化合物结构如式(IV)所示:
另外地,本发明还提供了所述α-突触核蛋白靶向化合物的制备方法,当所述α-突触核蛋白靶向化合物结构为式(I)时,制备方法包括以下步骤:
SI、以化合物14和化合物12或化合物36和化合物12作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,再经三氟乙酸/二氯甲烷脱保护,即得;
当所述α-突触核蛋白靶向化合物结构为式(II)时,制备方法包括以下步骤:
SII、以化合物18和化合物22或化合物39和化合物22作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,即得;
当所述α-突触核蛋白靶向化合物结构为式(III)时,制备方法包括以下步骤:
SIII、以化合物26和化合物27或化合物41和化合物27作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,即得;
其中,n为2或3。
本发明的α-突触核蛋白靶向化合物是一系列蛋白靶向降解嵌合体(proteolysistargeting chimera,PROTAC),基于相应的嵌合分子,其一端可与靶蛋白(α-突触核蛋白)特异性结合,而另一端可招募E3连接酶(cIAP、CRBN或VHL),从而形成靶蛋白-嵌合分子-E3连接酶的三元复合体系。在这一三元复合体系中,E3连接酶将对靶蛋白进行泛素化修饰,被泛素化的靶蛋白可被蛋白酶体识别,进而被选择性地降解、清除,达到蛋白靶向降解(targetedproteindegradation)的效果。而嵌合分子则将返回至胞质溶胶,继续诱导新的三元复合体系的形成。
因此,本发明还提供了所述α-突触核蛋白靶向化合物在制备治疗α-突触核蛋白相关疾病中的应用。
进一步地,所述α-突触核蛋白靶向化合物通过降解α-突触核蛋白来治疗疾病。
更进一步地,所述α-突触核蛋白相关疾病包括帕金森病、路易体痴呆、多系统萎缩。
另外地,本发明还提供了一种治疗α-突触核蛋白相关疾病的药物,所述药物包括所述α-突触核蛋白靶向化合物和/或其药学上可接受的盐、水合物、溶剂化物。
进一步地,所述药物为口服剂、注射剂、吸入剂或外用制剂。
本发明具有以下有益效果:
本发明提供了一类α-突触核蛋白靶向化合物,该类化合物同时包含α-突触核蛋白配体、连接子和E3连接酶配体结构片段,能够招募细胞内的E3连接酶对α-突触核蛋白进行泛素化修饰,进而借助UPS实现α-突触核蛋白的化学诱导降解;并且经试验证明,该类化合物可以达到显著降低α-突触核蛋白水平,提高细胞活力的效果,在治疗α-突触核蛋白相关疾病领域具有较好的应用前景。
附图说明
图1为本发明应用例1中化合物对胞内α-突触核蛋白聚集体降解作用测定的免疫印迹图像。
图2为本发明应用例2中化合物对胞内α-突触核蛋白聚集体降解作用的机制验证的免疫印迹图像。
图3为本发明应用例3中化合物对α-突触核蛋白聚集体相关细胞毒性降低作用的结果统计图。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,以下实施例所用试剂和材料均为市购。
实施例1 APD-A系列化合物的合成与结构确认
所述APD-A系列化合物的合成路线及条件如下:
(a)NaOH,Ba(OH)2·8H2O,MeOH,RT,24h;(b)H2O2,NaOH,MeOH,0℃to RT,24h;(c)NH2NH2·H2O,p-TsOH,toluene,90℃,4h;(d)DHP,p-TsOH,THF,reflux,24h;(e)H2,Pd/C,RT,24h;(f)(Boc2)O,Et3N,MeOH,reflux,3h;(g)p-TsCl,DMAP,DCM,RT,1h+1h;(h)(Boc2)O,NaOH,H2O/acetone,RT,24h;(i)DIEA,DMF,90℃,24h;(j)TFA,DCM,RT,2h;(k)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体方法及结构确认:
通用方法一(脱保护):
取约1mmol反应物溶于10mL二氯甲烷/三氟乙酸(1∶1)混合溶剂中,于室温、强烈搅拌下反应2h;反应毕,多次减压移除溶剂,真空干燥,得相应脱保护产物。
通用方法二(酰胺缩合):
取0.25mmol反应物A(胺)、0.25mmol反应物B(羧酸)和0.25mmol 1-羟基苯并三唑(38mg)溶于5mL N,N-二甲基甲酰胺中,冷至0℃,然后于搅拌下加入0.25mmol N,N-二异丙基乙胺(41μL)和0.25mmol N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐(48mg),缓慢恢复至室温,反应24h,反应毕,用水稀释,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(二氯甲烷/甲醇/三乙胺,95∶4∶1)纯化,真空干燥,得相应缩合产物。
化合物3的合成:
取2mmol 3,4-亚甲二氧苯乙酮(化合物1,328mg)、2mmol间硝基苯甲醛(化合物2,302mg)、1mmol氢氧化钠(40mg)和0.25mmol八水合氢氧化钡(79mg)悬于10mL甲醇,于室温下反应24h;反应毕,过滤,弃去滤液,滤出物用少量冷甲醇洗涤,所得粗品经乙酸乙酯/乙醇重结晶纯化,得化合物3,琥珀色晶体,收率80%。
1H NMR(400MHz,DMSO-d6)δ/ppm=6.18(s,2H);7.11(d,J=8.14Hz,1H);7.74(m,2H);7.82(d,J=15.58Hz,1H);7.94(d,J=8.19Hz,1H);8.15(d,J=15.59Hz,1H);8.27(d,J=8.13Hz,1H);8.34(d,J=7.65Hz,1H);8.79(s,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=102.64;108.52;108.68;123.42;125.02;125.16;125.98;130.79;132.41;135.61;137.18;141.38;148.55;148.92;152.31;187.28.HRMS(ESI)m/z calcd.for C16H12O5N+[(M+H)+]:298.07100,found:298.07105.
化合物4的合成:
取2mmol化合物3(594mg)悬于20mL甲醇,冷至0℃,然后于搅拌下加入1mL 30%双氧水和1mL 5%氢氧化钠水溶液,缓慢恢复至室温,反应24h;反应毕,过滤,弃去滤液,滤出物用少量冷甲醇洗涤,所得粗品经乙酸乙酯/乙醇重结晶纯化,得化合物4,白色针状晶体,收率80%。
1H NMR(400MHz,DMSO-d6)δ/ppm=4.35(s,1H);4.92(s,1H);6.16(s,2H);7.09(d,J=8.19Hz,1H);7.54(s,1H);7.74(q,J=8.20Hz,2H);7.91(d,J=7.64Hz,1H);8.24(d,J=8.37Hz,1H);8.29(s,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=57.77;59.71;102.77;107.88;108.85;121.67;124.06;125.93;130.44;130.58;133.57;138.74;148.47;148.58;152.85;190.85.HRMS(ESI)m/z calcd.for C16H11O6NNa+[(M+Na)+]:336.04786,found:336.04781.
化合物5的合成:
取1mmol化合物4(313mg)和30mg对甲苯磺酸溶于10mL甲苯,然后加入5mmol水合肼(80%水溶液,312μL),热至90℃反应4h;反应毕,冷至室温,减压移除溶剂,所得粗品经乙醇重结晶纯化,得化合物5,浅黄色针状晶体,收率60%。
1H NMR(400MHz,DMSO-d6)δ/ppm=6.08(s,2H);7.03(s,1H);7.34(s,2H);7.41(s,1H);7.74(s,1H);8.17(d,J=7.01Hz,1H);8.27(s,1H);8.64(s,1H);13.44(brs,1H).13CNMR(400MHz,DMSO-d6)δ/ppm=100.40;101.82;106.12;109.27;119.51;119.64;122.46;123.59;130.80;131.72;135.85;144.33;147.81;148.36;148.82;149.61.HRMS(ESI)m/zcalcd.for C16H10O4N3 -[(M-H)-]:308.06768,found:308.06804.
化合物6的合成:
取1mmol化合物5(307mg)和30mg对甲苯磺酸溶于10mL无水四氢呋喃,然后于氮气气氛下逐滴加入2mmol 3,4-二氢吡喃(183μL),热至回流反应24h;反应毕,冷至室温,减压移除溶剂,所得粗品经快速柱层析(石油醚/乙酸乙酯,1:1)纯化,真空干燥,得化合物6,白色固体,收率50%。
1H NMR(400MHz,CDCl3)δ/ppm=1.52(m,2H);1.77(dd,J=27.36,12.81Hz,2H);2.05(d,J=11.12Hz,1H);2.63(q,J=9.57Hz,1H);3.57(t,J=11.36Hz,1H);4.10(d,J=10.12Hz,1H);5.17(d,J=9.82Hz,1H);5.98(s,2H);6.58(s,1H);6.85(d,J=8.05Hz,1H);6.99(d,J=6.31Hz,2H);7.48(t,J=7.89Hz,1H);8.07(d,J=7.93Hz,1H);8.14(d,J=7.52Hz,1H);8.63(s,1H).13C NMR(400MHz,CDCl3)δ/ppm=22.94;24.85;29.68;67.83;84.46;101.50;103.80;108.65;109.37;120.67;122.33;123.06;123.56;129.39;131.61;135.28;145.91;148.03;148.34;148.62;148.75.HRMS(ESI)m/z calcd.for C21H20O5N3 +[(M+H)+]:394.13975,found:394.13983.
化合物7的合成:
取1mmol化合物6(393mg)和30mg 5%钯碳悬于10mL无水四氢呋喃,然后用足量氢气(1atm)置换体系内气相,于室温、强烈搅拌下反应24h;反应毕,用Celite硅藻土滤除不溶物,收集滤液,减压移除溶剂,所得粗品经快速柱层析(石油醚/乙酸乙酯,1:1)纯化,真空干燥,得化合物7,白色固体,收率80%。
1H NMR(400MHz,DMSO-d6)δ/ppm=1.25(s,1H);1.58(dd,J=20.63,10.79Hz,3H);1.83(d,J=12.91Hz,1H);1.98(s,1H);3.56(t,J=9.11Hz,1H);4.02(d,J=10.45Hz,1H);5.21(m,3H);6.09(s,2H);6.53-7.40(m,8H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.76;25.07;29.69;67.13;84.21;101.93;103.89;109.18;109.20;111.08;113.92;114.15;122.94;123.99;129.51;134.00;145.07;148.15;148.18;149.22;150.63.HRMS(ESI)m/zcalcd.for C21H22O3N3 +[(M+H)+]:364.16557,found:364.16566.
对照化合物sery308的合成:
与化合物7的制备方法基本相同,不同之处在于将起始原料中的化合物6换为等量的化合物5(307mg),得化合物sery308,白色固体。
1H NMR(400MHz,DMSO-d6)δ/ppm=4.79(brs,2H);6.04(s,2H);6.65(d,J=6.37Hz,1H);6.81(s,1H);6.89(s,1H);6.99(m,3H);7.34(m,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=101.07;101.73;106.79;108.84;111.41;115.34;116.25;123.96;127.67;129.87;134.15;144.48;147.06;147.94;148.11;148.33.HRMS(ESI)m/z calcd.for C16H14O2N3 +[(M+H)+]:280.10805,found:280.10810.
化合物10a的合成:
取1mmol氨基三聚乙二醇(化合物8a,149mg),溶于10mL甲醇/三乙胺(9:1)混合溶剂中,然后于搅拌下逐滴加入2mmol二碳酸二叔丁酯(459μL),热至回流反应3h;反应毕,冷至室温,减压移除溶剂,得化合物9a,无色油状液体;所得化合物无需进一步纯化,直接溶于5mL二氯甲烷,并加入30mg 4-二甲氨基吡啶,待用;另取2mmol(381mg)对甲苯磺酰氯,溶于25mL二氯甲烷;于室温、搅拌下,将后一溶液在1h时间内滴入前一溶液中,滴加毕,继续反应1h;反应毕,减压移除溶剂,所得粗品经快速柱层析(二氯甲烷/甲醇,95:5)纯化,真空干燥,得化合物10a,无色油状液体,两步总收率70%。
1H NMR(400MHz,CDCl3)δ/ppm=1.44(s,9H);2.45(s,3H);3.29(t,J=4.56Hz,2H);3.50(t,J=5.13Hz,2H);3.56(d,J=5.43Hz,4H);3.69(t,J=5.56Hz,2H);4.17(t,J=5.20Hz,2H);4.94(brs,1H);7.35(d,J=8.00Hz,2H);7.80(d,J=8.13Hz,2H).13C NMR(400MHz,CDCl3)δ/ppm=21.64;28.41;40.35;68.72;69.19;70.19;70.28;70.70;79.24;127.97;129.84;133.01;144.85;155.96.HRMS(ESI)m/z calcd.for C18H30O7NS+[(M+H)+]:404.17375,found:404.17371.
化合物10b的合成:
与化合物10a的制备方法基本相同,不同之处在于将起始原料中的化合物8a换为等量的氨基四聚乙二醇(化合物8b,193mg),得化合物10b,无色油状液体,两步总收率70%。
1H NMR(400MHz,CDCl3)δ/ppm=1.44(s,9H);2.45(s,3H);3.30(t,J=5.23Hz,2H);3.53(t,J=5.22Hz,2H);3.60(s,8H);3.70(t,J=4.84Hz,2H);4.16(t,J=4.85Hz,2H);5.30(brs,1H);7.34(d,J=7.96Hz,2H);7.80(d,J=8.00Hz,2H).13C NMR(400MHz,CDCl3)δ/ppm=21.65;28.43;40.37;68.71;69.23;70.23;70.52;70.78;79.19;127.99;129.83;133.03;144.81;155.98.HRMS(ESI)m/z calcd.for C20H34O8NS+[(M+H)+]:448.20003,found:448.19996.
化合物12的合成:
取1mmol乌苯美司(化合物10,308mg)悬于25mL丙酮,冷至0℃,然后于搅拌下逐滴加入2mmol二碳酸二叔丁酯(459μL)和1mL 10%氢氧化钠水溶液,缓慢恢复至室温,反应24h;反应毕,减压浓缩,用水稀释,用乙酸乙酯萃取,合并有机相,用10%柠檬酸水溶液、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(石油醚/乙酸乙酯,1:1)纯化,得化合物12,白色固体,收率80%。
1H NMR(400MHz,DMSO-d6)δ/ppm=0.83(d,J=5.26Hz,3H);0.86(d,J=5.50Hz,3H);1.27(s,9H);1.59(s,3H);2.82(dd,J=12.59,7.0Hz,1H);2.91(dd,J=13.08,9.17Hz,1H);3.53(s,1H);3.84(d,J=2.69Hz,1H);3.94(d,J=7.70Hz,1H);5.69(brs,1H);6.12(d,J=9.3Hz,1H);7.17-7.41(m,5H);7.98(d,J=6.85Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=23.92;24.88;28.46;34.73;40.77;55.80;55.98;66.60;77.95;126.03;128.62;128.82;138.83;155.65;173.05;174.47.HRMS(ESI)m/z calcd.for C21H33O6N2 +[(M+H)+]:409.23331,found:409.23330.
化合物14a的合成:
取0.5mmol化合物7(182mg)和0.55mmol化合物10a(222mg),溶于10mL N,N-二甲基甲酰胺中,然后加入2mmol N,N-二异丙基乙胺(330μL),热至90℃反应24h;反应毕,冷至室温,用水稀释,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(石油醚/乙酸乙酯,1:1)纯化,真空干燥,得化合物13a,白色无定形固体;所得化合物13a无需纯化,直接按通用方法一反应,得化合物14a(三氟乙酸盐),浅棕色固体,两步总收率35%。
1H NMR(400MHz,DMSO-d6)δ/ppm=3.35-3.42(m,4H);3.58-3.67(m,5H);3.76(s,2H);4.19(d,J=10.97Hz,1H);5.23(brs,1H);6.06(s,2H);6.49(s,1H);6.76(s,1H);6.93(t,J=9.96Hz,1H);7.15(t,J=8.47Hz,1H);7.30-7.49(m,4H).13C NMR(400MHz,DMSO-d6)δ/ppm=40.90;46.16;70.18;70.36;100.05;101.25;108.44;108.58;111.43;113.54;115.93;120.84;128.32;130.09;133.89;147.23;148.13;148.85;149.36.HRMS(ESI)m/zcalcd.for C22H26O4N4 +[(M+H)+]:411.20268,found:411.20275.
化合物14b的合成:
与化合物14a的制备方法基本相同,不同之处在于将起始原料中的化合物10a换为等量的化合物10b(246mg),得化合物14b,(三氟乙酸盐),浅棕色固体,两步总收率35%。
1H NMR(400MHz,DMSO-d6)δ/ppm=3.12(t,J=10.02Hz,2H);3.52-3.67(m,14H);5.20(brs,1H);6.07(s,2H);6.46(s,1H);6.78(s,1H);6.93-7.36(m,5H);7.59(t,J=9.96Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=40.82;46.23;70.10;70.33;70.42;72.25;99.98;101.11;108.68;108.89;111.24;113.57;115.95;121.35;128.33;130.84;134.12;147.55;148.27;148.89;150.56.HRMS(ESI)m/z calcd.for C34H47O8N4 +[(M+H)+]:455.22890,found:455.22888.
化合物APD-A1的合成:
按通用方法二反应,反应物A为化合物14a(103mg)、反应物B为化合物12(102mg),得化合物15a,浅黄色固体;所得化合物15a按通用方法一反应,得化合物APD-A1(三氟乙酸盐),浅棕色固体,两步总收率50%。所得化合物APD-A1可通过半制备液相色谱(C18柱,水/乙腈,1:1,含1‰三氟乙酸)进一步纯化。
1H NMR(400MHz,DMSO-d6)δ/ppm=0.87(s,6H);1.56(m,3H);2.79(d,J=6.23Hz;1H);2.91(d,J=7.60Hz;1H);3.35-3.64(m,13H);3.83(d,J=6.12Hz;1H);3.96(t,J=6.50Hz;1H);4.30(t,J=7.69Hz,1H);6.02(s,2H);6.25(brs,1H);6.51-7.51(m,13H);7.96(brs,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.40;24.99;37.51;40.36;40.73;43.24;52.56;55.76;69.60;69.65;69.86;70.54;101.34;101.69;106.90;108.94;112.51;114.51;119.61;120.57;127.22;128.78;129.41;132.13;137.16;145.76;147.75;148.33;149.36;150.11;173.87.HRMS(ESI)m/z calcd.for C38H49O7N6 +[(M+H)+]:701.36572;found:701.36571.
化合物APD-A2的合成:
与化合物APD-A1的制备方法基本相同,不同之处在于将起始原料中的化合物14a换为等量的化合物14b(114mg),得化合物APD-A2(三氟乙酸盐),浅棕色固体,两步总收率50%。
1H NMR(400MHz,DMSO-d6)δ/ppm=0.90(s,6H);1.49(m,1H);1.66(t,J=7.94Hz;2H);2.67(d,J=6.42Hz;1H);2.92(d,J=6.96Hz;1H);3.30-3.60(m,16H);3.66(d,J=7.03Hz;1H),3.91(t,J=7.90Hz;1H);4.39(t,J=9.39Hz,1H);6.03(s,2H);6.33(brs,1H);6.48-7.53(m,13H);7.82(brs,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.45;24.40;37.54;41.07;44.19;54.38;56.87;70.00;70.25;70.33;70.43;100.97;101.20;108.45;108.58;111.40;113.59;115.92;120.81;126.03;128.34;128.88;130.01;133.85;141.02;147.02;147.70;148.18;149.28;150.93;173.03.HRMS(ESI)m/z calcd.for C40H53O8N6 +[(M+H)+]:745.39194;found:745.39198.
实施例2 APD-B系列化合物的合成与结构确认
所述APD-B系列化合物的合成路线及条件:
(a)DIEA,DMF,90℃,24h;(b)TFA,DCM,RT,2h;(c)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体合成方法与结构确认:
化合物18的合成:
取0.5mmol化合物7(182mg)、1mmol N,N-二异丙基乙胺(164μL)溶于5mL N,N-二甲基甲酰胺,然后加入0.5mmol溴乙酸叔丁酯(化合物16,75μL),室温或热至90℃反应24h;反应毕,冷至室温,用水稀释,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(石油醚/乙酸乙酯,2:1)纯化,真空干燥,得化合物17,白色无定形固体;所得化合物17按通用方法一反应,得化合物18,浅棕色固体,两步总收率60%。
1H NMR(400MHz,DMSO-d6)δ/ppm=4.01(s,2H),6.07(s,2H);6.77(s,1H);6.84(s,1H);6.95(m,2H);7.25(m,3H);7.49(dd,J=11.14,6.12Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=45.65;99.52;101.17;108.41;108.49;111.47;113.46;115.62;120.65;147.65;129.99;133.78;147.66;148.13;148.85;149.42;172.29.HRMS(ESI)m/z calcd.forC18H16O4N3 +[(M+H)+]:338.34300,found:338.34288.
化合物22a的合成:
取0.73mmol 4-氟代沙利度胺(化合物19,200mg),1.1mmol化合物20a(273mg)和4mmol N,N-二异丙基乙胺(600μL),热至90℃反应24h;反应毕,冷至室温,用水稀释,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(石油醚/乙酸乙酯,2:1)纯化,真空干燥,得化合物21a,黄绿色无定形固体;所得化合物21a按通用方法一反应,得化合物22a(三氟乙酸盐),黄绿色无定形固体,两步总收率60%。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.51-2.60(m,2H);2.81-2.90(m,2H);3.25(m,2H);3.43(m,2H);3.54(m,4H);3.65(m,4H);4.98(t,J=5.62Hz,1H);6.99(d,J=6.22Hz,1H);7.29(d,J=7.85Hz.1H);7.82(d,J=5.98Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.35;28.44;41.67;45.56;62.64;70.11;70.20;72.21;112.29;116.18;117.14;132.77;137.34;147.67;168.05;168.82;173.84.HRMS(ESI)m/z calcd.for C19H25O6N4 +[(M+H)+]:405.17741;found:405.17688.
化合物22b的合成:
与化合物22a的制备方法基本相同,不同之处在于将起始原料中的化合物20a换为等量的化合物20b(321mg),得化合物22b,黄绿色无定形固体,两步总收率55%。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.53-2.60(m,2H);2.82-2.91(m,2H);3.23(m,2H);3.43(m,2H);3.55(m,4H);3.66(m,4H);4.99(t,J=5.75Hz,1H);7.01(d,J=6.31Hz,1H);7.31(d,J=7.79Hz.1H);7.80(d,J=6.08Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.38;28.39;41.66;45.60;62.75;70.12;70.18;70.24;72.26;112.10;116.24;117.19;132.81;137.10;147.65;168.12;168.88;173.90.HRMS(ESI)m/z calcd.for C21H29O7N4 +[(M+H)+]:449.20362;found:449.20303.
化合物APD-B1的合成:
按通用方法二反应,反应物A为化合物22a(101mg)、反应物B为化合物18(85mg),得化合物APD-B1,黄绿色无定形固体,收率50%。所得化合物APD-B1可通过半制备液相色谱(C18柱,水/乙腈,1:1,含1‰三氟乙酸)进一步纯化。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.53-2.61(m,2H);2.83-2.92(m,2H);3.26(m,2H);3.41(m,4H);3.47(s,4H);3.56(t,J=5.35Hz,2H);3.69(s,2H);5.06(dd,J=12.89,5.36Hz,1H);6.06(s,2H);6.52(d,J=7.85Hz,1H);6.57(t,J=5.59Hz,1H);6.95-7.06(m,4H);7.09(d,J=8.60Hz,1H);7.15(t,J=7.80Hz,1H);7.32(d,J=8.07Hz,1H);7.37(s,1H);7.56(t,J=8.36Hz,1H);7.87(t,J=5.65Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.22;27.01;29.04;29.49;34.44;38.91;42.11;47.39;49.03;60.24;69.27;69.54;70.01;70.10;99.48;101.56;105.98;109.05;109.69;111.14;117.83;119.24;129.74;130.12;132.53;136.67;146.83;148.17;149.09;167.77;169.41;170.56;170.73;170.85;173.30.HRMS(ESI)m/z calcd.for C37H38O9N7 +[(M+H)+]:724.27255;found:724.26965.
化合物APD-B2的合成:
与化合物APD-B1的制备方法基本相同,不同之处在于将起始原料中的化合物22a换为等量的化合物22b(112mg),得化合物APD-B2,黄绿色无定形固体,收率45%。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.53-2.61(m,2H);2.84-2.93(m,1H);3.25(m,2H);3.38(m,4H);3.43(m,6H);3.48(m,2H);3.51(m,2H);3.58(t,J=5.34Hz,2H);3.69(s,2H);5.06(dd,J=12.90,5.32Hz,1H);6.06(s,2H);6.53(d,J=5.39Hz,1H);6.58(t,J=5.73Hz,1H);6.94(s,1H);6.96-7.08(m,4H);7.09-7.20(m,2H);7.33(d,J=8.05Hz,1H);7.37(s,1H);7.56(t,J=8.10Hz,1H);7.89(t,J=5.64Hz,1H);11.10(s,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.61;31.45;38.90;42.13;47.38;49.02;55.39;69.31;69.48;70.01;70.19;99.49;101.58;105.99;109.07;109.40;109.70;111.14;117.89;119.22;129.73;132.55;136.68;146.85;147.29;148.18;149.10;167.76;169.40;170.56;170.67;173.29.HRMS(ESI)m/z calcd.for C39H42O10N7 +[(M+H)+]:768.29877;found:768.29559.
实施例3 APD-C系列化合物的合成与结构确认
所述APD-C系列化合物的合成路线与条件:
(a)CBr4,PPh3,DCM,0℃ to RT,12h;(b)DIEA,DMF,90℃,24h;(c)TFA,DCM,RT,2h;(d)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体制备方法与结构确认:
化合物24a的合成:
取1mmol羧基三聚乙二醇叔丁酯(化合物23a,234mg)溶于10mL二氯甲烷,冷至0℃,然后于搅拌下分批加入1mmol四溴化碳(331mg)和1mmol三苯基膦(262mg),于室温下反应12h;反应毕,减压移除溶剂,用水重悬,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(二氯甲烷/甲醇,95∶5)纯化,得化合物24a,橙色油状液体,收率60%。
1H NMR(400MHz,CDCl3)δ/ppm=1.42(s,9H),2.62(t,J=5.37Hz,2H);3.50-3.55(m,6H);3.74(t,J=5.47Hz,2H);3.85(t,J=6.23Hz,2H).13C NMR(400MHz,CDCl3)δ/ppm=28.79;30.71;33.30;66.95;69.42;69.71;70.10;82.16;173.11.HRMS(ESI)m/z calcd.forC11H22BrO4 +[(M+H)+]:297.06960;found:297.06690,299.06495.
化合物24b的合成:
与化合物24a的制备方法基本相同,不同之处在于将起始原料中的化合物23a换为等量的羧基四聚乙二醇叔丁酯(化合物17b,278mg),得化合物24b,橙色油状液体,收率60%。
1H NMR(400MHz,CDCl3)δ/ppm=1.47(s,9H),2.65(t,J=6.41Hz,2H);3.52-3.56(m,10H);3.73(t,J=6.58Hz,2H);3.87(t,J=6.90Hz,2H).13C NMR(400MHz,CDCl3)δ/ppm=28.82;31.00;33.25;66.84;69.36;69.65;70.11;70.41;81.98;173.08.HRMS(ESI)m/zcalcd.for C13H26BrO5 +[(M+H)+]:341.09581;found:341.09380,343.09171.
化合物26a的合成:
取0.5mmol化合物7(182mg)和0.55mmol化合物24a(163mg),溶于10mL N,N-二甲基甲酰胺,然后加入2mmol N,N-二异丙基乙胺(330μL),热至90℃反应24h;反应毕,冷至室温,用水稀释,用乙酸乙酯萃取,合并有机相,用水、食盐水分别洗涤,用无水硫酸镁干燥,所得粗品经快速柱层析(石油醚/乙酸乙酯,1:1)纯化,真空干燥,得化合物25a,淡黄色无定形固体;所得化合物25a按通用方法一反应,得化合物26a(三氟乙酸盐),浅棕色固体,两步总收率35%。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.24(t,J=8.64Hz,2H);3.46-3.52(m,6H);3.61-3.64(m,4H);6.05(s,2H);6.28(brs,1H);6.80(d,J=10.26Hz,2H);7.06(m,2H);7.23-7.27(m,3H);7.49(t,J=9.60Hz,1H);11.82(brs,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=35.57;43.24;63.51;69.54;69.67;69.86;100.13;101.57;106.90;108.94;112.51;114.51;119.60;120.56;127.02;129.43;132.28;145.80;147.86;148.28;148.50;149.88;177.02.HRMS(ESI)m/z calcd.for C23H26O6N3 +[(M+H)+]:440.18161;found:440.18020.
化合物26b的合成:
与化合物26a的制备方法基本相同,不同之处在于将起始原料中的化合物24a换为等量的化合物24b(188mg),得化合物26b(三氟乙酸盐),浅棕色固体,两步总收率35%。
1H NMR(400MHz,DMSO-d6)δ/ppm=2.29(t,J=7.80Hz,2H);3.46(t,J=5.81Hz,2H);3.52-3.58(m,8H);3.64-3.67(m,4H);6.05(s,2H);6.22(brs,1H);6.76(d,J=11.77Hz,2H);7.00(m,2H);7.26-7.30(m,3H);7.51(t,J=8.18Hz,1H);11.79(brs,1H).13CNMR(400MHz,DMSO-d6)δ/ppm=35.62;43.44;63.93;69.40;69.54;69.94;70.58;70.67;100.53;101.58;107.17;109.05;112.81;114.73;119.72;120.62;127.53;129.45;132.86;145.68;147.97;148.88;148.38;149.14;177.16.HRMS(ESI)m/z calcd.for C25H30O7N3 +[(M+H)+]:484.20783;found:484.20574.
化合物APD-C1的合成:
按通用方法二反应,反应物A为氨基-VH032(化合物27,107mg)、反应物B为化合物26a(110mg),得化合物APD-C1,浅黄色固体,收率60%。所得化合物APD-C1可通过半制备液相色谱(C18柱,水/乙腈,1:1,含1‰三氟乙酸)进一步纯化。
1H NMR(400MHz,DMSO-d6)δ/ppm=0.95(s,9H);1.46(d,J=6.21Hz,3H);2.14-2.17(m,2H);2.51-2.55(m,5H);3.46(t,J=10.55Hz,2H);3.56-3.70(m,10H);4.35-4.39(m,3H);4.50(s,1H);6.02(s,2H);6.25(brs,1H);6.78(d,J=11.97Hz,2H);6.93-7.00(m,2H);7.23-7.29(m,3H);7.43-7.49(m,3H);7.80(d,J=6.33Hz,2H);8.62(s,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=17.07;22.68;26.58;35.47;37.62;38.64;43.24;44.01;54.26;58.94;60.10;66.50;69.54;69.67;69.77;69.86;101.34;101.69;106.90;108.94;112.51;114.51;119.61;120.57;127.53;128.31;128.59;129.43;132.13;135.61;135.96;140.43;145.76;147.75;148.33;149.35;149.95;150.11;171.24;172.08;172.88.HRMS(ESI)m/zcalcd.for C46H56O8N7S+[(M+H)+]:866.39056;found:866.38684.
化合物APD-C2的合成:
与化合物APD-C1的制备方法基本相同,不同之处在于将起始原料中的化合物26a换为等量的化合物26b(121mg),得化合物APD-C2,浅黄色固体,收率60%。
1H NMR(400MHz,DMSO-d6)δ/ppm=1.00(s,9H);1.48(d,J=6.45Hz,3H);2.15-2.23(m,2H);2.49-2.55(m,2H);3.26(d,J=7.95Hz,1H);3.41-3.51(m,2H);3.53-3.75(m,14H);4.36-4.39(m,3H);4.53(d,J=10.30Hz,1H);6.07(s,2H);6.25(brs,1H);6.51(t,J=8.22Hz,1H);6.63(m,1H);6.92(d,J=8.30Hz,1H);7.11(s,1H);7.20-7.32(4H);7.40-7.57(m,4H);8.77(s,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=17.08;22.57;26.84;35.38;36.18;37.54;37.81;42.32;43.44;44.23;54.51;58.48;60.06;66.12;68.78;69.42;69.85;69.98;69.78;70.12;70.74;101.54;101.90;104.10;106.91;107.25;108.72;110.39;112.13;114.68;116.53;119.65;120.09;127.68;128.75;128.98;129.68;132.41;135.38;135.87;138.50;140.73;145.14;147.71;148.45;149.31;149.47;149.74;150.53;171.18;172.24;172.57;182.25.HRMS(ESI)m/z calcd.for C47H58O9N7S+[(M+H)+]:910.41677;found:910.41199.
实施例4 APD-D系列化合物的合成与结构确认
所述APD-D系列化合物的合成路线与条件:
(a)NaOH,Ba(OH)2·8H2O,MeOH,RT,24h;(b)Br2,CHCl3,0℃,4h;(c)NH2NH2·H2O,EtOH,reflux,24h;(d)DHP,p-TsOH,THF,reflux,24h;(e)H2,Pd/C,RT,24h;(f)DIEA,DMF,90℃,24h;(g)TFA,DCM,RT,2h;(h)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体制备方法与结构确认:
化合物30的合成:
与化合物3的制备方法基本相同,不同之处在于将起始原料中的化合物1和化合物2分别换为等量的间溴苯甲醛(化合物28,183mg)和对硝基苯乙酮(化合物29,165mg),得化合物30,橙色固体,收率80%。
1H NMR(400MHz,DMSO-d6)δ/ppm=7.36(t,J=7.51Hz,1H);7.52(m,2H);7.60(t,J=7.49Hz,1H);7.72(t,J=4.49Hz,1H);7.81(m,1H);8.07(m,2H);8.30(m,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=122.44;122.65;123.95;127.45;129.75;129.96;130.35;131.96;135.71;140.36;144.75;150.07;189.35.HRMS(ESI)m/z calcd.for C15H11O3NBr+[(M+H)+]:331.99168;found:331.98989,333.98785.
化合物31的合成:
取1mmol化合物30(332mg)悬于10mL氯仿,冷至0℃,待用。另取1mmol(55μL)溴素,溶于5mL氯仿,于0℃、搅拌下,将后一溶液逐滴加入前一溶液中,滴加毕,保持0℃反应2h;反应毕,用石油醚稀释,过滤,弃去滤液,滤出物用石油醚洗涤,得化合物31,橙色固体,收率90%。
1H NMR(400MHz,DMSO-d6)δ/ppm=5.55(d,J=6.92Hz,1H);5.86(d,J=7.14Hz,1H);7.29(m,2H);7.41(m,1H);7.58(m,1H);8.21(m,2H);8.30(m,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=48.27;48.65;122.48;124.03;127.91;129.47;130.43;130.59;131.64;136.46;139.27;149.93;191.76.HRMS(ESI)m/z calcd.for C15H11O3NBr3 +[(M+H)+]:488.82108;found:490.81903,492.81699.
化合物32的合成:
取1mmol化合物31(491mg)悬于10mL乙醇,然后加入5mmol水合肼(80%水溶液,312μL),热至回流,反应24h;反应毕,减压移除溶剂,用水重悬,过滤,弃去滤液,滤出物用水洗涤,所得粗品经乙醇重结晶纯化,得化合物32,橙色针状晶体,收率50%。
1H NMR(400MHz,DMSO-d6)δ/ppm=7.00(s);7.36(t,J=7.52Hz,1H);7.44(t,J=7.50Hz,1H);7.59(t,J=7.50Hz,1H);7.72(m,1H);7.90(m,2H);8.20(m,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=102.19;122.46;124.05;126.17;127.12;129.96;132.25;130.98;132.27;135.18;144.89;147.93;149.03.HRMS(ESI)m/z calcd.for C15H11O2N3Br+[(M+H)+]:344.00292;found:344.00090,345.99987.
化合物33的合成:
与化合物6的制备方法基本相同,不同之处在于将起始原料中的化合物5换为等量的32(344mg)得化合物33,黄色固体。
1H NMR(400MHz,DMSO-d6)δ/ppm=1.59-1.74(m,4H);1.92-2.17(m,2H);3.57-3.67(m,2H);5.21(brs,2H);5.80(t,J=7.20Hz,1H);6.79(s,1H);7.43-7.45(m,2H);7.67(d,J=7.15Hz,1H);7.78(d,J=6.83Hz,1H);7.97(d,J=6.01Hz,2H);8.26(d,J=5.97Hz,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=21.68;24.77;29.53;67.54;85.00;105.15;122.41;123.94;126.24;127.28;130.16;131.22;132.43;133.91;135.57;143.20;149.25;150.49.HRMS(ESI)m/z calcd.for C20H19O3N3Br+[(M+H)+]:428.06043;found:428.05793,430.05588.
化合物34的合成:
与化合物7的制备方法基本相同,不同之处在于将起始原料中的化合物6换为等量的化合物33(429mg),得化合物34,黄色固体。
1H NMR(400MHz,DMSO-d6)δ/ppm=1.66(m,2H);1.75(m,1H);1.96(m,1H);2.05(m,1H);2.36(m,1H);3.78(m,1H);3.86(m,1H);5.20(brs,2H);5.88(t,J=6.96Hz,1H);6.83(m,2H);7.06(s,1H);7.34(d,J=7.51Hz,1H);7.50(m,2H);7.64(m,2H);7.76(s,1H).13CNMR(400MHz,DMSO-d6)δ/ppm=21.73;24.72;29.53;67.54;84.91;104.98;114.86;121.97;126.14;127.55;128.38;130.04;131.37;132.33;132.81;143.48;149.79;149.85.HRMS(ESI)m/z calcd.for C20H19O3N3Br+[(M+H)+]:398.08625;found:398.08437,400.08232.
对照化合物sery384的合成:
与化合物34的制备方法基本相同,不同之处在于将起始原料中的化合物33换为等量的化合物32(344mg),得化合物sery384,黄色固体。
1H NMR(400MHz,DMSO-d6)δ/ppm=5.08(s,3H);6.92(m,4H);6.98(s,1H);7.38(t,J=7.42,3H);7.43(t,J=7.47Hz,2H);7.56-7.60(m,6H);7,74(t,J=5.52Hz,2H).13C NMR(400MHz,DMSO-d6)δ/ppm=102.17;114.46;122.49;126.45;127.15;129.76;129.95;130.94;132.13;144.86;148.99;149.95.HRMS(ESI)m/z calcd.for C15H13N3Br+[(M+H)+]:314.02874;found:314.02608,316.02403.
APD-D1、APD-D2的合成:
与从化合物7起始制备化合物APD-A1、APD-A2的方法基本相同,不同之处在于将起始原料中的化合物7换为等量的化合物34(199mg)。
化合物APD-D1,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=0.90(d,J=6.44Hz,6H);1.49(m,1H);1.76(m,2H);2.67(m,1H);2.92(m,1H);3.12(brs,1H);3.37-3.52(m,10H);3.64-3.67(m,4H);4.39-4.44(m,2H);6.01(brs,1H);6.51(d,J=9.82Hz,2H);6.81(s,1H);7.20-7.26(m,7H);7.43-7.45(m,2H);7.67(d,J=7.31Hz,3H);7.78(d,J=6.22Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.65;24.68;37.50;41.25;41.31;46.14;55.14;57.77;69.92;70.01;70.10;99.74;114.08;121.44;122.21;126.01;126.51;128.11;128.30;128.85;131.06;131.19;135.27;138.07;147.62;147.74;171.07;173.03.HRMS(ESI)m/z calcd.for C37H48O5N6Br+[(M+H)+]:735.28641;found:735.28645,737.28436.
化合物APD-D2,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=0.87(d,J=6.36Hz,6H);1.50-1.53(m,2H);1.82(m,1H);2.65(m,1H);2.81-2.84(m,2H);3.15(brs,1H);3.38(m,2H);3.48(m,2H);3.60-3.62(m,10H);4.26-4.34(m,2H);6.04(brs,1H);6.59(d,J=8.42Hz,2H);7.01(s,1H);7.14-7.31(m,8H);7.53(m,2H);7.74(m,2H);7.85(d,J=4.85Hz,1H).13C NMR(400MHz,DMSO-d6)δ/ppm=22.62;24.63;37.43;41.20;41.25;46.11;55.08;57.52;69.61;70.01;70.13;99.76;114.07;121.36;122.19;126.07;126.51;128.13;128.30;128.81;131.05;131.18;135.24;138.07;147.58;147.70;171.04;173.01.HRMS(ESI)m/z calcd.for C39H52O6N6Br+[(M+H)+]:779.31262;found:779.31245,781.31058.
实施例5 APD-E系列化合物的合成与结构确认
所述APD-E系列化合物的合成路线:
(a)DIEA,DMF,90℃,24h;(b)TFA,DCM,RT,2h;(c)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体制备方法与结构确认:
化合物APD-E1、APD-E2的合成:
与从化合物7起始制备化合物APD-B1、APD-B3的方法基本相同,不同之处在于将起始原料中的化合物7换为等量的化合物34(199mg)。
化合物APD-E1,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=2.02-2.27(m,4H);3.46-3.62(m,12H);5.44(t,J=6.96Hz,1H);6.47(brs,1H);6.61(d,J=7.44Hz,2H);6.81(s,1H);6.98(d,J=7.73Hz,2H);7.25-7.45(m,3H),7.67(m,3H);7.75(m,1H).HRMS(ESI)m/z calcd.for C34H34O6N6Br+[(M+H)+]:701.17177;found:701.16898,703.16693.
化合物APD-E2,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=2.07-2.23(m,4H);3.45-3.52(m,12H);3.60-3.63(m,4H);5.50(t,J=7.50Hz,1H);6.35(brs,1H);6.51(d,J=6.39Hz,2H);6.78(s,1H);6.86(d,J=5.92Hz,1H);7.20(d,J=6.83Hz,1H);7.40-7.45(m,2H);7.55(m,1H);7.62-7.66(m,3H);7.78(d,J=6.48Hz,1H).HRMS(ESI)m/z calcd.forC36H38O7N6Br+[(M+H)+]:745.19799;found:745.19421,747.19216.
实施例6 APD-F系列化合物的合成与结构确认
所述APD-F系列化合物的合成路线:
(a)DIEA,DMF,90℃;(b)TFA,DCM,RT,2h;(c)EDC·HCl,HOBT,DIEA,DMF,RT,24h.
具体制备方法与结构确认:
化合物APD-F1、APD-F2的合成:
与从化合物7起始制备化合物APD-C1、APD-C2的方法基本相同,不同之处在于将起始原料中的化合物7换为等量的化合物34(199mg)。
化合物APD-F1,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=0.97(s,9H);1.50(d,J=6.89Hz,3H);2.15(dd,J=13.63,8.13Hz,2H);2.54(m,2H);2.66(s,3H);3.37(t,J=8.01Hz,2H);3.60-3.71(m,10H);3.96(m,1H);4.07(m,1H);4.12(t,J=11.49Hz,1H);4.36(dd,J=15.16,5.26Hz,2H);4.49(m,1H);4.54(brs,1H);4.75(s,1H);6.51(d,J=7.88Hz,2H);7.33-7.41(m,3H);7.45-7.50(m,2H);7.67-7.72(m,3H);7.77-7.80(m,3H);8.99(s,1H).HRMS(ESI)m/z calcd.for C44H53O6N7SBr+[(M+H)+]:886.29559;found:886.29108,888.28904.
化合物APD-F2,黄色固体。1H NMR(400MHz,DMSO-d6)δ/ppm=1.01(s,9H);1.53(d,J=6.88Hz,3H);2.11(dd,J=8.80,4.43Hz,2H);2.51(m,2H);2.68(s,3H);3.48(t,J=8.85Hz,2H);3.46-3.69(m,14H);3.73(d,J=8.13Hz,2H);4.00(m,1H);4.15(t,J=9.55Hz,1H);4.23(dd,J=11.37,7.12Hz,2H);4.44(m,1H);4.50(brs,1H);4.88(s,1H);6.62(d,J=8.27Hz,2H);7.44-7.49(m,3H);7.47-7.53(m,2H);7.60-7.70(m,3H);7.78-7.83(m,3H);8.87(s,1H).HRMS(ESI)m/z calcd.for C46H57O7N7SBr+[(M+H)+]:930.32181;found:930.32016,932.31811.
应用例1化合物对胞内α-突触核蛋白聚集体降解作用的测定
化合物准备:
将合成得到的各化合物(经HPLC检验纯度)以1000倍工作浓度溶于DMSO中,制成相应的贮备液,贮备液可于4℃、避光条件下短期保存,临用时于培养体系中稀释至工作浓度。
细胞培养:
人神经母细胞瘤细胞SH-SY5Y被接种在DMEM完全培养基中(含10%胎牛血清、100U/mL青霉素和0.1mg/mL链霉素),于37℃、5%CO2气氛下培养,并按通用方法进行传代。
质粒载体的构建:
编码人α-突触核蛋白(含6×His标签)的cDNA被分别克隆至pET28a(用于原核表达)和pcDNA3.1(用于真核表达)质粒载体中。所得载体被转入大肠杆菌(Escherichiacoli)DH5α感受态菌株,并按通用方法进行转化、提取和纯化。
重组α-突触核蛋白的表达和纯化:
将pET28a-SNCA-6×His转入E.coli BL21(DE3)感受态菌株中,涂布于含10μg/mL卡那霉素的LB平板上过夜培养。次日,挑取单克隆接种至含10μg/mL卡那霉素的液体LB培养基中,于37℃、200rpm下培养至OD600=0.6,随即加入异丙基-β-D-硫代半乳糖苷(IPTG)至终浓度为1mg/mL,继续培养6h。培养毕,离心收集细菌沉淀,并按试剂指引裂解、离心,获得蛋白样品。所得蛋白样品按试剂盒指引,使用His亲和凝胶纯化,洗脱的重组α-突触核蛋白经SDS-PAGE检验后,使用超滤法脱盐、浓缩,并用BCA或微量分光光度法测定其浓度。
α-突触核蛋白预制纤维(PFF)的制备:
将纯化的重组α-突触核蛋白于微量离心管中以PBS稀释至5mg/mL,于37℃、1000rpm下孵育7d。孵育毕,可见明显淀粉样浑浊产生,将所得浊液(粒径大于5μm)适当分装,即得α-突触核蛋白PFF一级贮备液,可于-80℃长期保存。临用时将一级贮备液以PBS稀释至100μg/mL,并超声破碎60s至澄清(粒径为100~1000nm),即得α-突触核蛋白PFF二级贮备液。
α-突触核蛋白聚集细胞模型的构建:
在SH-SY5Y细胞上,采用PFF播种(PFF seeding)联合SNCA瞬时转染的方法构建模拟病理性α-突触核蛋白聚集的细胞模型。取对数生长期的SH-SY5Y细胞接种于6孔板上,过夜培养使其充分贴壁,然后采用Lipofectamine 2000转染试剂,按制造商所提供的标准方法,将pcDNA3.1-SNCA-6×His转入细胞中,并继续培养12h使表达。12h后,采用Lipofectamine 2000转染试剂,按制造商所提供的标准方法(以上述PFF二级贮备液代替DNA溶液,使PFF终浓度为1μg/mL),将PFF导入细胞,并继续培养12h使蛋白聚集体形成。
药物处理:
模型构建毕,弃去培养基,用PBS充分漂洗以除去任何残留的PFF,然后换用含相应浓度(8~1000nM)待测化合物的完全培养基,继续培养24h。
蛋白水平的测定:
采用免疫印迹法测定各条件下细胞内α-突触核蛋白的水平。药物处理毕,收集细胞,加入SDS裂解液(含蛋白酶抑制剂混合物),于冰上裂解20min,并辅以超声破碎。充分裂解后,于4℃、12000RCF下离心10min,取上清,经BCA法测定蛋白浓度后,加入5×上样缓冲液,然后于4℃变性处理10min。所收获的蛋白样品被装载至SDS-PAGE凝胶上,按通用方法电泳分离、转至PVDF膜上进行免疫反应,最后利用化学发光法显影。利用Image J软件量化显影图像,以GAPDH为内参,计算各组中细胞内α-突触核蛋白的水平,并基于此评估相应条件下的蛋白降解作用。
本发明评估了所述12种α-突触核蛋白靶向化合物及化合物sery308、sery384对胞内α-突触核蛋白聚集体的降解作用。其中,化合物sery308、sery384为对照化合物,其与所述α-突触核蛋白靶向降解化合物的α-突触核蛋白配体部分具有一致的化学结构,但不具有能与E3连接酶相结合的结构。本发明以1μM化合物处理24h后细胞内α-突触核蛋白的降解率(D)为指标,评估化合物对α-突触核蛋白聚集体的降解作用。D可按下式计算:
其中DMSO处理组为阴性对照,蛋白本底水平指不经任何处理(包括PFF播种、转染和化合物处理)的SH-SY5Y细胞中α-突触核蛋白的表达水平。测试所得免疫印迹图像示于图1,计算所得降解率D列于表1。
表1化合物对胞内α-突触核蛋白聚集体的降解作用
由结果可见,经1μM所述各α-突触核蛋白靶向化合物处理后,胞内α-突触核蛋白聚集体水平均显著下降,其中降解效果最优的为化合物APD-B1,其在1μM浓度下对α-突触核蛋白聚集体的降解率D=60.59±3.77%。而经1μM化合物sery308或sery384处理后,胞内α-突触核蛋白聚集体水平无显著变化。
应用例2化合物对胞内α-突触核蛋白聚集体降解作用的机制验证
以APD-B1为代表性化合物,采用溶酶体/蛋白酶体抑制法,验证化合物对α-突触核蛋白聚集体降解作用的机制。如应用例1所述构建模拟α-突触核蛋白聚集的细胞模型。模型构建毕,弃去培养基,用PBS充分漂洗以除去任何残留的PFF,然后换用含1μM化合物APD-B1和10μM磷酸氯喹(CQ,溶酶体抑制剂)或5μM MG-132(蛋白酶体抑制剂)的完全培养基,继续培养24h。药物处理毕,如应用例1所述测定各组中蛋白水平,并评估相应条件下的蛋白降解作用。测试所得免疫印迹图像示于图2。
由结果可见,当10μM CQ存在时,1μM化合物APD-B1对α-突触核蛋白聚集体的降解作用无显著变化。而当5μM MG-132存在时,1μM化合物APD-B1对α-突触核蛋白聚集体的降解作用显著减弱。该结果表明,化合物对α-突触核蛋白聚集体水平的调控作用不依赖于溶酶体的活性而依赖于蛋白酶体的活性,即化合物通过UPS相关的靶向降解机制调控α-突触核蛋白聚集体的水平。
应用例3化合物对胞内α-突触核蛋白聚集体相关细胞毒性降低作用的测定
采用CCK-8法检测各组中的细胞活力。将对数生长期的SH-SY5Y细胞接种在96孔板上,过夜培养使其充分贴壁,然后如应用例1所述构建模拟α-突触核蛋白聚集的细胞模型并予药物处理。药物处理毕,弃去培养基,换用含CCK-8的DMEM完全培养基孵育1h,于酶联免疫检测仪450nm处检测各孔对应的吸光度值,以不经任何处理(包括PFF播种、转染和化合物处理)的SH-SY5Y细胞为对照组,计算各组的相对细胞活力(以与对照组细胞活力的比值百分数表示),并基于此评估各相应条件下化合物对α-突触核蛋白聚集体相关细胞毒性的降低作用。
本发明评估了所述12种α-突触核蛋白靶向化合物及化合物sery308、sery384对α-突触核蛋白聚集体相关细胞毒性的降低作用。测试结果示于图3。
由结果可见,经PFF播种联合SNCA瞬时转染处理后,SH-SY5Y细胞的细胞活力显著下降。经1μM所述各α-突触核蛋白靶向化合物处理后,细胞活力均有所回升。其中细胞毒性降低效果最优的为化合物APD-B1,其在1μM浓度下将细胞活力从53.48±2.05%提升至84.46±2.62%。而经1μM化合物sery308或sery384处理后,细胞活力无显著变化。
综上所述,发明人提供了一类α-突触核蛋白靶向化合物,并通过免疫印迹法评估了该类化合物对胞内α-突触核蛋白聚集体的降解作用,通过CCK-8法评估了该类化合物对α-突触核蛋白聚集体相关细胞毒性的降低作用。结果一致表明,该类化合物可在较低的浓度(1μM)下有效地降解胞内的α-突触核蛋白,并降低其相关的细胞毒性。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
2.根据权利要求1所述α-突触核蛋白靶向化合物,其特征在于,所述化合物具有式(II)所示结构。
5.权利要求1~4任一所述α-突触核蛋白靶向化合物的制备方法,其特征在于,当所述α-突触核蛋白靶向化合物结构为式(I)时,制备方法包括以下步骤:
SI、以化合物14和化合物12或化合物36和化合物12作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,再经三氟乙酸/二氯甲烷脱保护,即得;
当所述α-突触核蛋白靶向化合物结构为式(II)时,制备方法包括以下步骤:
SII、以化合物18和化合物22或化合物39和化合物22作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,即得;
当所述α-突触核蛋白靶向化合物结构为式(III)时,制备方法包括以下步骤:
SIII、以化合物26和化合物27或化合物41和化合物27作为原料,N,N-二甲基甲酰胺为溶剂,在N,N-二异丙基乙胺、1-羟基苯并三唑和N-(3-二甲基氨基丙基)-N′-乙基碳二亚胺盐酸盐作用下,0~25℃反应完全,即得;
其中,n的定义与权利要求1~4定义一致。
6.权利要求1~4任一所述α-突触核蛋白靶向化合物在制备治疗α-突触核蛋白相关疾病中的应用。
7.根据权利要求6所述应用,其特征在于,所述α-突触核蛋白靶向化合物通过降解α-突触核蛋白来治疗疾病。
8.根据权利要求6所述应用,其特征在于,所述α-突触核蛋白相关疾病包括帕金森病、路易体痴呆、多系统萎缩。
9.一种治疗α-突触核蛋白相关疾病的药物,其特征在于,包括权利要求1~4任一所述α-突触核蛋白靶向化合物和/或其药学上可接受的盐、水合物、溶剂化物。
10.根据权利要求9所述药物,其特征在于,所述药物为口服剂、注射剂、吸入剂或外用制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210159074.4A CN114573570B (zh) | 2022-02-21 | 2022-02-21 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210159074.4A CN114573570B (zh) | 2022-02-21 | 2022-02-21 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114573570A true CN114573570A (zh) | 2022-06-03 |
CN114573570B CN114573570B (zh) | 2023-05-30 |
Family
ID=81770172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210159074.4A Active CN114573570B (zh) | 2022-02-21 | 2022-02-21 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114573570B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115475164A (zh) * | 2022-08-22 | 2022-12-16 | 西安交通大学 | 一种可降解PDGFR-β的蛋白降解靶向嵌合体及其制备方法和应用 |
CN115650957A (zh) * | 2022-09-16 | 2023-01-31 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056903A (zh) * | 2008-06-09 | 2011-05-11 | 路德维希马克西米利安慕尼黑大学 | 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 |
CN102170787A (zh) * | 2008-10-03 | 2011-08-31 | 普罗蒂奥科技有限公司 | 用于治疗β-淀粉样蛋白病和突触核蛋白病的化合物、组合物和方法 |
CN112672993A (zh) * | 2018-07-24 | 2021-04-16 | 普罗泰克株式会社 | 新autotac嵌合化合物及包含其的通过靶向的蛋白质降解来预防、改善或治疗疾病的组合物 |
CN112912376A (zh) * | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
CN115124590A (zh) * | 2022-07-05 | 2022-09-30 | 武汉大学中南医院 | 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用 |
-
2022
- 2022-02-21 CN CN202210159074.4A patent/CN114573570B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056903A (zh) * | 2008-06-09 | 2011-05-11 | 路德维希马克西米利安慕尼黑大学 | 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 |
CN102170787A (zh) * | 2008-10-03 | 2011-08-31 | 普罗蒂奥科技有限公司 | 用于治疗β-淀粉样蛋白病和突触核蛋白病的化合物、组合物和方法 |
CN112672993A (zh) * | 2018-07-24 | 2021-04-16 | 普罗泰克株式会社 | 新autotac嵌合化合物及包含其的通过靶向的蛋白质降解来预防、改善或治疗疾病的组合物 |
CN112912376A (zh) * | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
CN115124590A (zh) * | 2022-07-05 | 2022-09-30 | 武汉大学中南医院 | 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
梁倩倩等: "PROTACs 靶向蛋白质降解技术及其在合理药物设计中的应用", 《中国新药杂质》 * |
谢妙红等: "小分子蛋白降解靶向嵌合体的研究进展", 《中国现代应用药学》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115475164A (zh) * | 2022-08-22 | 2022-12-16 | 西安交通大学 | 一种可降解PDGFR-β的蛋白降解靶向嵌合体及其制备方法和应用 |
CN115650957A (zh) * | 2022-09-16 | 2023-01-31 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
CN115650957B (zh) * | 2022-09-16 | 2023-12-15 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114573570B (zh) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114573570A (zh) | 一类α-突触核蛋白靶向化合物及其制备方法和应用 | |
US7396843B2 (en) | 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | |
US7151118B2 (en) | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | |
AU2009220974B2 (en) | Azetidine derivatives | |
US7183297B2 (en) | Biphenyl-derivatives as p38-kinase inhibitors | |
EA023955B1 (ru) | Производное аминоалкилзамещенного n-тиенилбензамида | |
US8227504B2 (en) | Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof | |
CN87103693A (zh) | 喹啉-3-羟酸衍生物和其制备及应用 | |
CA3057415A1 (en) | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators | |
EP1611086A1 (en) | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | |
CA2871237A1 (en) | Benzamide derivative | |
JP2008546638A (ja) | 新規なオピオイド化合物の組成物およびその使用方法 | |
TW200811135A (en) | NK-1 and serotonin transporter inhibitors | |
EP0875501B1 (en) | Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug | |
AU2014312756A1 (en) | Novel aromatic compound and use thereof | |
US8754095B2 (en) | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | |
WO2008071665A1 (en) | A nicotinamide derivative useful as p38 kinase inhibitor | |
CN115260194B (zh) | 新型egfr降解剂 | |
US8859588B2 (en) | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof | |
CZ20001815A3 (cs) | Deriváty difenylamidinu | |
CS210036B1 (cs) | Deriváty ergolinu-l | |
MXPA06009022A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |